Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Affiris AG

www.affiris.com

Latest From Affiris AG

Lundbeck Breaks Into MAb Development, Adds To Suite Of Parkinson's Candidates

Denmark's mid-sized biopharma, Lundbeck, has taken another potential Parkinson's disease therapeutic into early clinical studies, the third this year, and this time it's a monoclonal antibody, not a small molecule.

 

Neurology Research & Development

AZ Partners Parkinson's Compound With Takeda

The deal, worth up to $400m, will see the companies develop an early-stage alpha-synuclein antibody, a hot area of research in Parkinson's disease.

Neurology Companies

Venture Funding Deals, September 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced July through August 2015.

BioPharmaceutical Medical Device

Praluent, Repatha: FDA guinea pigs to market trailblazers

Sanofi's and Regeneron Pharmaceuticals' Praluent (alirocumab) and Amgen's Repatha (evolocumab) not only are the guinea pigs for how the FDA will handle the first proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor applications, but the drugs also are expected to be trailblazers in the marketplace for what's coming behind them – notably Pfizer's bococizumab, which is catching up fast to the two leaders.

Guinea
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Affiris GMBH
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Austria
  • Parent & Subsidiaries
  • Affiris AG
  • Senior Management
  • Oliver Siegel, CEO
    Richard Westmoreland, CFO
    Arne von Bonin, PhD, CSO
    Achim Schneeberger, MD, CMO
  • Contact Info
  • Affiris AG
    Phone: (43) (1)-7981575-300
    Karl-Farkas-Gasse 22
    Vienna, 1030
    Austria
UsernamePublicRestriction

Register